Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
This article was originally published in The Pink Sheet Daily
Executive Summary
Focused on protein misfolding disorders, FoldRx has a lead candidate under review at EMA for transthyretin amyloid polyneuropathy.